Etzer Darout
Stock Analyst at BMO Capital
(1.91)
# 2,975
Out of 4,840 analysts
111
Total ratings
32.14%
Success rate
-6.99%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Etzer Darout
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TERN Terns Pharmaceuticals | Maintains: Outperform | $26 → $15 | $3.01 | +398.34% | 5 | May 13, 2025 | |
| VERV Verve Therapeutics | Maintains: Buy | $18 → $24 | $4.29 | +459.44% | 2 | Apr 15, 2025 | |
| IVA Inventiva | Maintains: Buy | $12 → $9 | $3.36 | +167.86% | 3 | Apr 4, 2025 | |
| ARVN Arvinas | Maintains: Outperform | $82 → $20 | $6.69 | +198.95% | 4 | Mar 12, 2025 | |
| PTGX Protagonist Therapeutics | Reiterates: Outperform | $62 → $72 | $46.43 | +55.07% | 2 | Mar 11, 2025 | |
| BNTX BioNTech SE | Maintains: Outperform | $130 → $143 | $98.55 | +45.10% | 4 | Mar 11, 2025 | |
| QTTB Q32 Bio | Downgrades: Market Perform | $22 → $3 | $1.68 | +78.57% | 3 | Feb 11, 2025 | |
| IGMS IGM Biosciences | Downgrades: Market Perform | $21 → $2 | $1.22 | +63.93% | 2 | Jan 10, 2025 | |
| EXEL Exelixis | Downgrades: Market Perform | $36 → $40 | $43.09 | -7.17% | 3 | Dec 20, 2024 | |
| TRML Tourmaline Bio | Initiates: Outperform | $50 | $15.50 | +222.58% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $9.77 | +258.24% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $55 | $28.11 | +95.69% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $63 | $4.77 | +1,220.75% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $27 | $1.10 | +2,354.55% | 7 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $132 → $134 | $72.27 | +85.42% | 6 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $32 → $34 | $7.75 | +338.71% | 5 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 → $48 | $21.28 | +125.56% | 3 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $118 → $120 | $113.21 | +6.00% | 3 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $38 | $30.46 | +24.75% | 3 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $25 | $4.41 | +466.89% | 6 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $8 → $5 | $1.49 | +236.70% | 9 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $1.30 | +1,438.46% | 3 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $84 → $91 | $50.80 | +79.13% | 5 | Jun 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $7 → $6 | $1.22 | +391.80% | 7 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $3.25 → $3.59 | $2.13 | +68.94% | 10 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $82 | $70.96 | +15.56% | 4 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $19 | $4.03 | +371.46% | 2 | Apr 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $170 | $290.10 | -41.40% | 2 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $54 | $46.00 | +17.39% | 1 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $27 → $38 | $43.87 | -13.38% | 2 | Sep 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $52 | $1.27 | +3,994.49% | 1 | Mar 28, 2018 |
Terns Pharmaceuticals
May 13, 2025
Maintains: Outperform
Price Target: $26 → $15
Current: $3.01
Upside: +398.34%
Verve Therapeutics
Apr 15, 2025
Maintains: Buy
Price Target: $18 → $24
Current: $4.29
Upside: +459.44%
Inventiva
Apr 4, 2025
Maintains: Buy
Price Target: $12 → $9
Current: $3.36
Upside: +167.86%
Arvinas
Mar 12, 2025
Maintains: Outperform
Price Target: $82 → $20
Current: $6.69
Upside: +198.95%
Protagonist Therapeutics
Mar 11, 2025
Reiterates: Outperform
Price Target: $62 → $72
Current: $46.43
Upside: +55.07%
BioNTech SE
Mar 11, 2025
Maintains: Outperform
Price Target: $130 → $143
Current: $98.55
Upside: +45.10%
Q32 Bio
Feb 11, 2025
Downgrades: Market Perform
Price Target: $22 → $3
Current: $1.68
Upside: +78.57%
IGM Biosciences
Jan 10, 2025
Downgrades: Market Perform
Price Target: $21 → $2
Current: $1.22
Upside: +63.93%
Exelixis
Dec 20, 2024
Downgrades: Market Perform
Price Target: $36 → $40
Current: $43.09
Upside: -7.17%
Tourmaline Bio
Dec 6, 2024
Initiates: Outperform
Price Target: $50
Current: $15.50
Upside: +222.58%
Dec 6, 2024
Initiates: Outperform
Price Target: $35
Current: $9.77
Upside: +258.24%
Dec 6, 2024
Initiates: Market Perform
Price Target: $55
Current: $28.11
Upside: +95.69%
Dec 6, 2024
Initiates: Outperform
Price Target: $63
Current: $4.77
Upside: +1,220.75%
Nov 14, 2024
Maintains: Outperform
Price Target: $28 → $27
Current: $1.10
Upside: +2,354.55%
Nov 13, 2024
Maintains: Outperform
Price Target: $132 → $134
Current: $72.27
Upside: +85.42%
Nov 8, 2024
Reiterates: Outperform
Price Target: $32 → $34
Current: $7.75
Upside: +338.71%
Nov 8, 2024
Reiterates: Outperform
Price Target: $46 → $48
Current: $21.28
Upside: +125.56%
Oct 30, 2024
Maintains: Market Perform
Price Target: $118 → $120
Current: $113.21
Upside: +6.00%
Oct 11, 2024
Maintains: Outperform
Price Target: $34 → $38
Current: $30.46
Upside: +24.75%
Aug 13, 2024
Maintains: Outperform
Price Target: $26 → $25
Current: $4.41
Upside: +466.89%
Aug 7, 2024
Maintains: Market Perform
Price Target: $8 → $5
Current: $1.49
Upside: +236.70%
Aug 6, 2024
Reiterates: Outperform
Price Target: $20
Current: $1.30
Upside: +1,438.46%
Jun 4, 2024
Maintains: Outperform
Price Target: $84 → $91
Current: $50.80
Upside: +79.13%
May 10, 2024
Maintains: Market Perform
Price Target: $7 → $6
Current: $1.22
Upside: +391.80%
May 9, 2024
Maintains: Market Perform
Price Target: $3.25 → $3.59
Current: $2.13
Upside: +68.94%
Apr 26, 2024
Maintains: Outperform
Price Target: $80 → $82
Current: $70.96
Upside: +15.56%
Apr 25, 2023
Maintains: Outperform
Price Target: $20 → $19
Current: $4.03
Upside: +371.46%
Feb 3, 2022
Upgrades: Buy
Price Target: $170
Current: $290.10
Upside: -41.40%
Feb 26, 2021
Initiates: Buy
Price Target: $54
Current: $46.00
Upside: +17.39%
Sep 9, 2020
Maintains: Buy
Price Target: $27 → $38
Current: $43.87
Upside: -13.38%
Mar 28, 2018
Maintains: Outperform
Price Target: $54 → $52
Current: $1.27
Upside: +3,994.49%